The purpose of this research is to learn whether the investigational study drug BMS-986504 works to treat metastatic (cancer that has spread in the body) pancreatic ductal adenocarcinoma (PDAC) when combined with standard chemotherapy in participants with homozygous MTAP deletion or MTAP loss, who have not previously received treatment for metastatic PDAC.

Do you have Crohn's disease and painful period cramps? You may be able to join a research study. We want to learn which pain medicine works best and is safest for people with Crohn's disease.

Are you interested in learning about your sleep, satiety, energy, and cognition? Interested in protein? You may be able to participate in a research study to find out how a plant-based protein, creatine, and fiber supplement may impact those outcomes.

Do you have moderate to severe plaque psoriasis? If so, you may qualify for a clinical research study evaluating an investigational treatment for plaque psoriasis.

Do you identify as Hispanic? Do you regularly buy beverages for your household? If so, you may be eligible to participate in a research study about what makes people decide to buy things in a convenience store. Compensation provided.

This study is being conducted to see how well a study drug called ponsegromab works and if it might improve health and quality of life compared to a placebo in adults who have cachexia (a condition causing significant unintentional weight loss and muscle wasting) and metastatic pancreatic cancer, for which they receive initial chemotherapy.

Are you a Korean speaker living in the U.S. who has used a medical interpreter in a hospital? We are conducting a study to learn about your communication experiences with interpreters and healthcare providers. You can choose to complete a short online survey or participate in a one-on-one interview in Korean. You may enter a drawing based on chance in which each participant has equal odds of receiving the incentive for the survey and receive a gift card for participating in the interview. The study has been modified to broaden the survey participant criteria to include individuals who have not used medical interpreter services, in addition to those who have.

We're doing this study to understand how a type of genetic material called DNA in the blood changes in people with a specific type of cancer that has spread to only a few places in the body. By looking at how this DNA behaves before and after cancer treatment, including radiation, we aim to learn more about how the cancer responds. To do this, we'll collect blood and tumor samples from you to analyze what's happening. This could help in better understanding and improving cancer treatments for others in the future.

Do you have IgE mediated food allergies? Are you interested in the benefits of anti-IgE medications but are hoping to receive fewer injections? RPT904 is expected to work by blocking IgE antibodies, similar to a United States Food and Drug Administration (FDA) approved drug called omalizumab (available as Xolair® or generic omalizumab). However, RPT904 is designed to stay in the body longer than omalizumab and therefore require fewer injections.

Are you living with primary biliary cholangitis (PBC) and are taking or plan to take elafibranor for your condition? Consider joining our registry study to help advance treatment options and patient quality of life with this condition. We invite you to participate to discuss your experience and the impact on your condition seen with elafibranor. By joining, you'll contribute to understanding the effectiveness and safety of elafibranor in treating PBC. The study aims to evaluate its impact on itching, fatigue, sleep, and overall quality of life. Your participation is voluntary, and you can withdraw at any time without losing medical benefits. With approximately 424 participants globally, you'll continue to receive treatment as usual during the 5-year study period. Plus, you'll have opportunities to discuss your experience with our team and have your voice heard regarding your experience with elafibranor and it's effect on your quality of life with PBC.